# SMMT earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SMMT) · [Earnings tab](https://www.lopjlb.com/stock/SMMT?tab=earnings) Updated: 2026-10-19T01:27:20 Quarters analyzed: 8 ## Cross-quarter narrative Across eight earnings calls spanning 2023 Q4 to 2026 Q2, Summit Therapeutics moved from vague guidance and minimal data to a densely populated pipeline with multiple Phase III readouts, regulatory filings and sizable capital infusions. Early calls highlighted cash sufficiency for Phase III trials and on‑track milestones for HARMONi and HARMONi‑3. By Q3 2024 the company reported a positive PFS signal for HARMONi‑2 and announced new programs (HARMONi‑7, non‑NSCLC expansion) while raising $235 M. Subsequent quarters added Chinese NMPA approval, a Pfizer ADC partnership, and a growing portfolio of collaborations (MD Anderson, GSK, Revolution, GORTEC). Capital grew to over $700 M, supporting accelerated enrollment and manufacturing diversification. Throughout, management repeatedly flagged regulatory uncertainty, OS‑data immaturity, competitive bispecific pressure and reliance on Akeso for manufacturing and Chinese trials. While demand visibility sharpened with physician enthusiasm and enrollment speed, execution risks (protocol amendments, regional enrollment imbalances) persisted. The most recent calls show completed enrollment for HARMONi‑3, a BLA under FDA review and consistent OS benefit signals, indicating a shift from exploratory to near‑commercial stages, yet key risks remain unresolved. ## Latest CallCard · Q2 Summit Therapeutics reports strong ivonescimab data with consistent OS benefit across regions, enrollment complete for HARMONi-3, BLA under FDA review and cash at $690.7M, while event timing pushes PFS readouts to late 2026. **Guidance:** maintained — BLA submission is under FDA review with a target PDUFA date of November 14, and the company expects potential U.S. approval and launch later this year. **Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.3 Prepared remarks highlighted positive OS data, multiple Phase III completions, expanding pipeline and strong cash position, conveying optimism. ### Demand visibility Growing physician support and expanding trial enrollment signal strong demand visibility. Ivonescimab has been dosed in over 4,000 trial patients and over 70,000 commercial patients in China, with increasing physician interest and multiple global collaborations. ### Capital allocation Cash $690.7M, $231M raised via ATM, new $380M ATM facility, no debt. Operating cash used $140M in Q2, GAAP operating expenses $220.5M, financing strategy relies on ATM facilities for flexibility. ### Milestones - **HARMONi (global Phase III)** [delivered]: Updated OS analysis shows hazard ratio 0.76 with consistent benefit across Western and Asian patients. - **HARMONi-3 (squamous cohort)** [on_track]: Enrollment completed; primary PFS events expected in the second half of 2026 with interim OS look thereafter. - **HARMONi-3 (non‑squamous cohort)** [on_track]: Events for PFS analysis expected in the first half of 2027; OS interim also planned for that period. - **HARMONi-7** [on_track]: Enrollment continues strong; updates forthcoming. - **HARMONi‑GI3** [on_track]: Phase III trial ongoing, evaluating ivonescimab plus chemo versus bevacizumab plus chemo in colorectal cancer. - **ILLUMINE (head‑and‑neck)** [on_track]: Enrolling in Europe, planned China start later this year, U.S. sites under evaluation. - **RevMed collaboration** [new]: First‑quarter 2026 enrollment began for ivonescimab with three novel RAS inhibitors across solid tumors. - **GSK collaboration** [new]: First patient expected to enroll later this quarter in combination with GSK's B7‑H3 ADC. ### Fears / risks - **Regulatory risk**: FDA review of the BLA with a target PDUFA date; approval is not guaranteed. - **Statistical significance**: Uncertainty whether interim OS analyses will achieve statistical significance. - **Enrollment variability**: Potential imbalance in regional enrollment could affect event maturity and readout timing. - **Alpha spending**: Multiple interim OS looks raise concerns about alpha allocation. - **Competitive landscape**: Need to demonstrate superiority over existing PD‑1 inhibitors. - **Financial burn**: Rising operating expenses and cash usage could pressure liquidity. - **Market adoption**: Commercial success depends on continued physician support and uptake beyond China. - **Collaboration dependence**: Success of novel‑novel combos relies on partners RevMed, GSK and Arcus delivering data. ### Key quotes > “I'm very proud of the highly focused, mission-driven patient-first team at Summit and the growing physician support around ivonescimab, our PD-1/VEGF bispecific and lead investigational asset.” — Robert Duggan > “We ended the second quarter of 2026 with a strong cash position of approximately $690.7 million as compared to $598.7 million at the end of first quarter of 2026.” — Manmeet Soni > “The submission is currently under review with the U.S. FDA. The agency has provided a target PDUFA date of November 14 of this year.” ## Quarter one-liners - **2026 Q2:** Summit Therapeutics reports strong ivonescimab data with consistent OS benefit across regions, enrollment complete for HARMONi-3, BLA under FDA review and cash at $690.7M, while event timing pushes PFS readouts to late 2026. - **2025 Q4:** Summit completed HARMONi-3 squamous enrollment, added interim PFS analysis for Q2 2026, BLA accepted for EGFR mutant NSCLC with Nov 2026 PDUFA, $713M cash, expanding Phase III program with new collaborations (GSK, Revolution Medicines, GORTEC ILLUMINE). - **2025 Q3:** — - **2025 Q1:** Summit highlights ivonescimab NMPA approval in China, positive OS trend (HR 0.777), HARMONi-6 PFS win vs tislelizumab+chemo, and mid-2025 HARMONi top-line readout; 11 Phase III trials underway. - **2024 Q4:** Summit Therapeutics advances Ivonescimab with Pfizer ADC collaboration, HARMONi top-line data expected mid-2025, HARMONi-3 expanded to squamous/non-squamous, HARMONi-7 initiated, targeting NSCLC and beyond. - **2024 Q3:** Summit Therapeutics reports Q3 2024 progress: HARMONi-2 Phase 3 shows ivonescimab superiority vs pembrolizumab in 1L NSCLC (HR 0.51 PFS), amends HARMONi-3 to include non-squamous (1,080 pts), plans HARMONi-7 in PD-L1 high (780 pts), raises $235M, explores expansion beyond NSCLC. - **2024 Q1:** Summit Therapeutics advances ivonescimab Phase III trials HARMONi (2L EGFRm NSCLC) and HARMONi-3 (1L squamous NSCLC) with $157M cash runway through Q1 2025; awaits Akeso's HARMONi-A China decision Q2 2024 as potential catalyst. - **2023 Q4:** — ## Theme arcs - **Clinical progress** (improving): Milestones moved from on‑track to delivered, with multiple Phase III readouts and BLA filing - **Capital position** (improving): Cash rose from $157 M to >$700 M through successive raises - **Regulatory risk** (stable): Ongoing FDA and NMPA reviews, approval not guaranteed - **Market demand visibility** (improving): Physician support and enrollment speed increased, though global commercial demand still early - **Manufacturing diversification** (new): Technology transfer for a second supply source initiated - **Partner dependency (Akeso)** (stable): Continued reliance for Chinese trials and manufacturing - **Competitive landscape** (deteriorating): Emerging PD‑1/VEGF bispecifics and ADCs increase pressure - **Trial execution risk** (stable): Protocol amendments and regional enrollment variability noted each quarter - **Expansion beyond NSCLC** (new): Programs announced for colorectal, head‑and‑neck and other solid tumors - **Collaboration expansion** (improving): New partnerships with Pfizer, GSK, Revolution, MD Anderson ## Guidance path 2023 Q4:vague → 2024 Q1:maintained → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/SMMT`